Compare Ginkgo Bioworks Holdings Inc (DNA) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Gold Fields Limited — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Gold Fields Limited trades at $36.82 (market cap $31.87B). The key difference: Gold Fields Limited is far larger — about 41.7× Ginkgo Bioworks Holdings Inc's market cap, and Gold Fields Limited pays a 6% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Gold Fields Limited for 49 Days on average.
| DNA | GFI | |
|---|---|---|
Market Cap | $763.64M | $31.87B |
Volume | 3,204,177 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $61.52 |
52-Week Low | $5.48 | $31.25 |
Typical Hold Time | 7 Days | 49 Days |
Enterprise Value | $865.59M | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.
The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
